The latest guidelines, however, stress on starting ART within the first two weeks of anti-TB treatment for patients with CD4 counts less than 50 cells/mm3 and within eight weeks for persons with higher CD4 counts.54 The exact timing of ART for TB and HIV co-treatment still remains unclear, as clinicians deal with adverse reactions, adherence, immune reconstitution and other problems that are associated with it. This evidence concerns the gene CD4 and tuberculosis.